Cargando…
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Autores principales: | Mangsbo, Sara M, Broos, Sissela, Gustafsson, Erika, Furebring, Christina, Veitonmäki, Niina, Dahlen, Eva, Norlen, Per, Lindstedt, Malin, Tötterman, Thomas, Ellmark, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991342/ http://dx.doi.org/10.1186/2051-1426-1-S1-P42 |
Ejemplares similares
-
Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015) -
The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014) -
Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015) -
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
por: Ellmark, Peter, et al.
Publicado: (2016) -
Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
por: Freiburghaus, Catja, et al.
Publicado: (2013)